Analysts Set Encompass Health Corporation (NYSE:EHC) Price Target at $143.86

Encompass Health Corporation (NYSE:EHC) has been assigned an average rating of “Buy” from the nine research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $143.8571.

EHC has been the subject of a number of research analyst reports. Weiss Ratings reiterated a “buy (b-)” rating on shares of Encompass Health in a report on Monday, June 8th. Leerink Partners set a $152.00 target price on Encompass Health in a research report on Friday, May 22nd. Barclays cut their target price on Encompass Health from $153.00 to $140.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 5th. Wall Street Zen raised Encompass Health from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Finally, TD Cowen began coverage on Encompass Health in a research report on Thursday, May 28th. They set a “buy” rating and a $125.00 target price on the stock.

Insider Activity

In related news, EVP Patrick William Tuer sold 682 shares of Encompass Health stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $104.56, for a total transaction of $71,309.92. Following the transaction, the executive vice president owned 24,755 shares of the company’s stock, valued at $2,588,382.80. The trade was a 2.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. lifted its position in shares of Encompass Health by 3,059,159.7% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 3,793,482 shares of the company’s stock valued at $402,640,000 after buying an additional 3,793,358 shares during the last quarter. AlphaCore Capital LLC purchased a new position in shares of Encompass Health during the 4th quarter valued at $4,881,000. JPMorgan Chase & Co. lifted its position in shares of Encompass Health by 5.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,410,335 shares of the company’s stock valued at $179,141,000 after buying an additional 70,387 shares during the last quarter. Tudor Investment Corp ET AL grew its stake in Encompass Health by 155.3% in the 3rd quarter. Tudor Investment Corp ET AL now owns 210,712 shares of the company’s stock valued at $26,765,000 after buying an additional 128,191 shares in the last quarter. Finally, SG Americas Securities LLC grew its stake in Encompass Health by 1,070.9% in the 4th quarter. SG Americas Securities LLC now owns 88,054 shares of the company’s stock valued at $9,346,000 after buying an additional 80,534 shares in the last quarter. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Encompass Health Trading Down 0.9%

Shares of EHC stock opened at $101.49 on Tuesday. The company has a market cap of $10.07 billion, a P/E ratio of 16.94, a PEG ratio of 2.21 and a beta of 0.72. The stock has a 50 day simple moving average of $104.31 and a two-hundred day simple moving average of $104.65. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.17 and a current ratio of 1.17. Encompass Health has a fifty-two week low of $92.77 and a fifty-two week high of $127.99.

Encompass Health (NYSE:EHC) last issued its earnings results on Thursday, April 30th. The company reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.51 by $0.09. The business had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.57 billion. Encompass Health had a return on equity of 18.28% and a net margin of 10.04%.The firm’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.37 earnings per share. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. Research analysts forecast that Encompass Health will post 5.97 earnings per share for the current year.

Encompass Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Wednesday, July 1st will be given a dividend of $0.19 per share. The ex-dividend date of this dividend is Wednesday, July 1st. This represents a $0.76 annualized dividend and a dividend yield of 0.7%. Encompass Health’s payout ratio is presently 12.69%.

Encompass Health Company Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.